{"id":7493,"date":"2021-09-09T13:44:15","date_gmt":"2021-09-09T17:44:15","guid":{"rendered":"https:\/\/www.millerthomson.com\/deals-cases\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/"},"modified":"2026-01-20T18:49:03","modified_gmt":"2026-01-20T23:49:03","slug":"mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars","status":"publish","type":"deals-cases","link":"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/","title":{"rendered":"MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars"},"content":{"rendered":"<p>Le 9\u00a0septembre\u00a02021, MYND Life Sciences Inc. (CSE\u00a0: MYND) (OTC\u00a0: MYNDF) (\u00ab\u00a0MYND\u00a0\u00bb) a conclu un placement priv\u00e9 sans interm\u00e9diaire dans le cadre duquel elle a vendu des unit\u00e9s de d\u00e9bentures convertibles (les \u00ab\u00a0unit\u00e9s de d\u00e9bentures\u00a0\u00bb) pour un montant total de 3\u00a0000\u00a0000\u00a0$. Cette transaction a permis de mobiliser un produit brut de 2\u00a0700\u00a0000\u00a0$.<\/p>\n<p>Chaque unit\u00e9 de d\u00e9benture se compose i) de d\u00e9bentures convertibles de premier rang non garanties d\u2019un capital de 1\u00a0000\u00a0$; et ii) de bons de souscription d\u2019actions ordinaires pouvant \u00eatre exerc\u00e9s pour souscrire 1\u00a0000\u00a0actions ordinaires de MYND.<\/p>\n<p>MYND Life Sciences est une soci\u00e9t\u00e9 de biotechnologie m\u00e9dicale et de recherche et d\u00e9veloppement de m\u00e9dicaments dont les activit\u00e9s sont ax\u00e9es sur le d\u00e9veloppement de m\u00e9dicaments neuro-pharmaceutiques et de nouveaux m\u00e9dicaments psych\u00e9d\u00e9liques, de m\u00e9thodes diagnostiques et de vaccins.<\/p>\n<p>L\u2019\u00e9quipe de Miller Thomson qui a conseill\u00e9 MYND \u00e9tait compos\u00e9e de Rhea Solis (march\u00e9s financiers et valeurs mobili\u00e8res) et d\u2019Anca Nitu (parajuriste).<\/p>\n","protected":false},"author":1,"template":"","class_list":["post-7493","deals-cases","type-deals-cases","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars | Miller Thomson<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars | Miller Thomson\" \/>\n<meta property=\"og:description\" content=\"Conseill\u00c3\u00a8re juridique de MYND Life Sciences Inc.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/\" \/>\n<meta property=\"og:site_name\" content=\"Miller Thomson\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MillerThomsonLaw\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T23:49:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@millerthomson\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/\",\"url\":\"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/\",\"name\":\"MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars | Miller Thomson\",\"isPartOf\":{\"@id\":\"https:\/\/www.millerthomson.com\/fr\/#website\"},\"datePublished\":\"2021-09-09T17:44:15+00:00\",\"dateModified\":\"2026-01-20T23:49:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.millerthomson.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transactions et mandats\",\"item\":\"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.millerthomson.com\/fr\/#website\",\"url\":\"https:\/\/www.millerthomson.com\/fr\/\",\"name\":\"Miller Thomson | Cabinet de droit des affaires pancanadien\",\"description\":\"National law firm providing business law expertise and litigation and disputes services for businesses across Canada since 1957.\",\"publisher\":{\"@id\":\"https:\/\/www.millerthomson.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.millerthomson.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.millerthomson.com\/fr\/#organization\",\"name\":\"Miller Thomson | Cabinet de droit des affaires pancanadien\",\"url\":\"https:\/\/www.millerthomson.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.millerthomson.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.millerthomson.com\/wp-content\/uploads\/2024\/10\/miller-thomson.svg\",\"contentUrl\":\"https:\/\/www.millerthomson.com\/wp-content\/uploads\/2024\/10\/miller-thomson.svg\",\"width\":380,\"height\":50,\"caption\":\"Miller Thomson | Cabinet de droit des affaires pancanadien\"},\"image\":{\"@id\":\"https:\/\/www.millerthomson.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/MillerThomsonLaw\/\",\"https:\/\/x.com\/millerthomson\",\"https:\/\/www.linkedin.com\/company\/miller-thomson-llp\/\",\"https:\/\/www.youtube.com\/@millerthomson\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars | Miller Thomson","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/","og_locale":"fr_FR","og_type":"article","og_title":"MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars | Miller Thomson","og_description":"Conseill\u00c3\u00a8re juridique de MYND Life Sciences Inc.","og_url":"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/","og_site_name":"Miller Thomson","article_publisher":"https:\/\/www.facebook.com\/MillerThomsonLaw\/","article_modified_time":"2026-01-20T23:49:03+00:00","twitter_card":"summary_large_image","twitter_site":"@millerthomson","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/","url":"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/","name":"MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars | Miller Thomson","isPartOf":{"@id":"https:\/\/www.millerthomson.com\/fr\/#website"},"datePublished":"2021-09-09T17:44:15+00:00","dateModified":"2026-01-20T23:49:03+00:00","breadcrumb":{"@id":"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/mynd-life-sciences-conclut-un-placement-prive-sans-intermediaire-entierement-souscrit-de-3-millions-de-dollars\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.millerthomson.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Transactions et mandats","item":"https:\/\/www.millerthomson.com\/fr\/transactions-et-causes\/"},{"@type":"ListItem","position":3,"name":"MYND Life Sciences conclut un placement priv\u00e9 sans interm\u00e9diaire enti\u00e8rement souscrit de 3 millions de dollars"}]},{"@type":"WebSite","@id":"https:\/\/www.millerthomson.com\/fr\/#website","url":"https:\/\/www.millerthomson.com\/fr\/","name":"Miller Thomson | Cabinet de droit des affaires pancanadien","description":"National law firm providing business law expertise and litigation and disputes services for businesses across Canada since 1957.","publisher":{"@id":"https:\/\/www.millerthomson.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.millerthomson.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.millerthomson.com\/fr\/#organization","name":"Miller Thomson | Cabinet de droit des affaires pancanadien","url":"https:\/\/www.millerthomson.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.millerthomson.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.millerthomson.com\/wp-content\/uploads\/2024\/10\/miller-thomson.svg","contentUrl":"https:\/\/www.millerthomson.com\/wp-content\/uploads\/2024\/10\/miller-thomson.svg","width":380,"height":50,"caption":"Miller Thomson | Cabinet de droit des affaires pancanadien"},"image":{"@id":"https:\/\/www.millerthomson.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MillerThomsonLaw\/","https:\/\/x.com\/millerthomson","https:\/\/www.linkedin.com\/company\/miller-thomson-llp\/","https:\/\/www.youtube.com\/@millerthomson"]}]}},"_links":{"self":[{"href":"https:\/\/www.millerthomson.com\/fr\/wp-json\/wp\/v2\/deals-cases\/7493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.millerthomson.com\/fr\/wp-json\/wp\/v2\/deals-cases"}],"about":[{"href":"https:\/\/www.millerthomson.com\/fr\/wp-json\/wp\/v2\/types\/deals-cases"}],"author":[{"embeddable":true,"href":"https:\/\/www.millerthomson.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.millerthomson.com\/fr\/wp-json\/wp\/v2\/deals-cases\/7493\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.millerthomson.com\/fr\/wp-json\/wp\/v2\/media?parent=7493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}